Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 47 articles:
HTML format



Single Articles


    August 2021
  1. BUTLER LM, Mah CY, Machiels J, Vincent AD, et al
    Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition.
    Cancer Res. 2021 Aug 6. pii: 0008-5472.CAN-20-3863.
    PubMed     Abstract available


    July 2021
  2. LABRECQUE MP, Brown LG, Coleman IM, Lakely B, et al
    RNA splicing factors SRRM3 and SRRM4 distinguish molecular phenotypes of castration-resistant neuroendocrine prostate cancer.
    Cancer Res. 2021 Jul 26. pii: 0008-5472.CAN-21-0307.
    PubMed     Abstract available


  3. EL-KENAWI A, Dominguez-Viqueira W, Liu M, Awasthi S, et al
    Macrophage-derived cholesterol contributes to therapeutic resistance in prostate cancer.
    Cancer Res. 2021 Jul 23. pii: 0008-5472.CAN-20-4028.
    PubMed     Abstract available


  4. MAVURA MY, Huang FW
    How Cancer Risk SNPs May Contribute to Prostate Cancer Disparities.
    Cancer Res. 2021;81:3764-3765.
    PubMed     Abstract available


    June 2021
  5. PALLMANN N, Deng K, Livgard M, Tesikova M, et al
    Stress mediated reprogramming of prostate cancer one-carbon cycle drives disease progression.
    Cancer Res. 2021 Jun 28. pii: 0008-5472.CAN-20-3956.
    PubMed     Abstract available


  6. WEI J, Yin L, Li J, Wang J, et al
    Bidirectional Crosstalk between MAOA and AR Promotes Hormone-Dependent and Castration-Resistant Prostate Cancer.
    Cancer Res. 2021 Jun 24. pii: 0008-5472.CAN-21-0198.
    PubMed     Abstract available


  7. HUANG Z, Tang B, Yang Y, Yang Z, et al
    MAP3K7-IKK inflammatory signaling modulates AR protein degradation and prostate cancer progression.
    Cancer Res. 2021 Jun 22. pii: 0008-5472.CAN-20-4194.
    PubMed     Abstract available


  8. ENRIQUEZ C, Cancila V, Ferri R, Sulsenti R, et al
    Castration-induced down-regulation of SPARC in stromal cells drives neuroendocrine differentiation of prostate cancer.
    Cancer Res. 2021 Jun 21. pii: 0008-5472.CAN-21-0163.
    PubMed     Abstract available


  9. SENA LA, Denmeade SR
    Fatty acid synthesis in prostate cancer: vulnerability or epiphenomenon?
    Cancer Res. 2021 Jun 18. pii: 0008-5472.CAN-21-1392.
    PubMed     Abstract available


    May 2021
  10. OSMULSKI PA, Cunsolo A, Chen M, Qian Y, et al
    Contacts with macrophages promote an aggressive nanomechanical phenotype of circulating tumor cells in prostate cancer.
    Cancer Res. 2021 May 27. pii: 0008-5472.CAN-20-3595.
    PubMed     Abstract available


  11. MATSUSHITA M, Fujita K, Hayashi T, Kayama H, et al
    Gut microbiota-derived short-chain fatty acids promote prostate cancer growth via IGF-1 signaling.
    Cancer Res. 2021 May 26. pii: 0008-5472.CAN-20-4090.
    PubMed     Abstract available


  12. MARTINEZ RS, Salji MJ, Rushworth L, Ntala C, et al
    SLFN5 regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer.
    Cancer Res. 2021 May 13. pii: 0008-5472.CAN-20-3694.
    PubMed     Abstract available


  13. RAHMAN NIA, Sato A, Tsevelnorov K, Shimizu A, et al
    Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth.
    Cancer Res. 2021;81:2318-2331.
    PubMed     Abstract available


  14. LIU Z, Guo C, Das SK, Yu X, et al
    Engineering T Cells to Express Tumoricidal MDA-7/IL24 Enhances Cancer Immunotherapy.
    Cancer Res. 2021;81:2429-2441.
    PubMed     Abstract available


    April 2021
  15. MATTHIAS J, Engelhardt J, Schafer M, Bauder-Wust U, et al
    Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies.
    Cancer Res. 2021;81:2234-2245.
    PubMed     Abstract available


  16. LACHANCE J
    Beyond Stamp Collecting: Evolutionary and Functional Genomics Advance Our Understanding of Cancer Biology.
    Cancer Res. 2021;81:1637-1638.
    PubMed     Abstract available


    March 2021
  17. CARRENO DV, Corro NB, Cerda-Infante JF, Echeverria CE, et al
    Dietary Fructose Promotes Prostate Cancer Growth.
    Cancer Res. 2021 Mar 24. pii: 0008-5472.CAN-19-0456.
    PubMed     Abstract available


  18. SHI L, Yan Y, He Y, Yan B, et al
    Mutated SPOP E3 ligase promotes 17betaHSD4 protein degradation to drive androgenesis and prostate cancer progression.
    Cancer Res. 2021 Mar 24. pii: 0008-5472.CAN-20-3258.
    PubMed     Abstract available


  19. WANG J, Wang J, Dai J, Jung Y, et al
    Retraction: A Glycolytic Mechanism Regulating an Angiogenic Switch in Prostate Cancer.
    Cancer Res. 2021;81:1623.
    PubMed    


  20. ZHOU Y, Jin X, Ma J, Ding D, et al
    HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer.
    Cancer Res. 2021;81:1486-1499.
    PubMed     Abstract available


    February 2021
  21. UNNO K, Chalmers ZR, Pamarthy S, Vatapalli R, et al
    Activated ALK Cooperates with N-Myc via Wnt/beta-catenin Signaling to Induce Neuroendocrine Prostate Cancer.
    Cancer Res. 2021 Feb 26. pii: 0008-5472.CAN-20-3351.
    PubMed     Abstract available


  22. XIE J, Rice MA, Chen Z, Cheng Y, et al
    In vivo imaging of methionine aminopeptidase II for prostate cancer risk stratification.
    Cancer Res. 2021 Feb 26. pii: 0008-5472.CAN-20-2969.
    PubMed     Abstract available


  23. HAN D, Owiredu JN, Healy BM, Li M, et al
    Susceptibility-associated genetic variation in NEDD9 contributes to prostate cancer initiation and progression.
    Cancer Res. 2021 Feb 25. pii: 0008-5472.CAN-20-3042.
    PubMed     Abstract available


  24. PASCHALIS A, Welti J, Neeb AJ, Yuan W, et al
    JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.
    Cancer Res. 2021;81:1087-1100.
    PubMed     Abstract available


  25. STROBL MAR, West J, Viossat Y, Damaghi M, et al
    Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy.
    Cancer Res. 2021;81:1135-1147.
    PubMed     Abstract available


  26. CENTENERA MM, Scott JS, Machiels J, Nassar ZD, et al
    ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer.
    Cancer Res. 2021 Feb 5. pii: 0008-5472.CAN-20-2511.
    PubMed     Abstract available


    January 2021
  27. GHOOCHANI A, Hsu EC, Aslan M, Rice MA, et al
    Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer.
    Cancer Res. 2021 Jan 22. pii: 0008-5472.CAN-20-3477.
    PubMed     Abstract available


  28. DHIMOLEA E, de Matos Simoes R, Kansara D, Weng X, et al
    Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment.
    Cancer Res. 2021;81:371-383.
    PubMed     Abstract available


  29. SOLEIMANY AP, Kirkpatrick JD, Su S, Dudani JS, et al
    Activatable Zymography Probes Enable In Situ Localization of Protease Dysregulation in Cancer.
    Cancer Res. 2021;81:213-224.
    PubMed     Abstract available


    December 2020
  30. ALPSOY A, Utturkar SM, Carter BC, Dhiman A, et al
    BRD9 is a critical regulator of androgen receptor signaling and prostate cancer progression.
    Cancer Res. 2020 Dec 21. pii: 0008-5472.CAN-20-1417.
    PubMed     Abstract available


  31. HAGIWARA M, Yasumizu Y, Yamashita N, Rajabi H, et al
    MUC1-C ACTIVATES THE BAF (mSWI/SNF) COMPLEX IN PROSTATE CANCER STEM CELLS.
    Cancer Res. 2020 Dec 15. pii: 0008-5472.CAN-20-2588.
    PubMed     Abstract available


  32. EMAMI NC, Cavazos TB, Rashkin SR, Graff RE, et al
    A large-scale association study detects novel rare variants, risk genes, functional elements, and polygenic architecture of prostate cancer susceptibility.
    Cancer Res. 2020 Dec 8. pii: 0008-5472.CAN-20-2635.
    PubMed     Abstract available


  33. GAO L, Zhang W, Zhang J, Liu J, et al
    KIF15-mediated stabilization of AR and AR-V7 contributes to enzalutamide resistance in prostate cancer.
    Cancer Res. 2020 Dec 4. pii: 0008-5472.CAN-20-1965.
    PubMed     Abstract available


    November 2020
  34. BOWEN C, Shibata M, Zhang H, Bergren SK, et al
    CRISPR/Cas9-Mediated Point Mutation in Nkx3.1 Prolongs Protein Half-Life and Reverses Effects Nkx3.1 Allelic Loss.
    Cancer Res. 2020;80:4805-4814.
    PubMed     Abstract available


  35. LI G, Kanagasabai T, Lu W, Zou MR, et al
    KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis.
    Cancer Res. 2020;80:4633-4643.
    PubMed     Abstract available


    October 2020
  36. SAWANT DESSAI A, Palestino Dominguez M, Chen UI, Hasper J, et al
    Transcriptional repression of SIRT3 potentiates mitochondrial aconitase activation to drive aggressive prostate cancer to the bone.
    Cancer Res. 2020 Oct 28. pii: 0008-5472.CAN-20-1708.
    PubMed     Abstract available


    September 2020
  37. BEKETOVA E, Fang S, Owens JL, Liu S, et al
    Protein arginine methyltransferase 5 promotes pICln-dependent androgen receptor transcription in castration-resistant prostate cancer.
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-20-1228.
    PubMed     Abstract available


  38. SHAH N, Kesten N, Font-Tello A, Chang MEK, et al
    ERG-mediated coregulator complex formation maintains androgen receptor signaling in prostate cancer.
    Cancer Res. 2020 Sep 15. pii: 0008-5472.CAN-20-2044.
    PubMed     Abstract available


  39. WANG C, Li J
    A deep learning framework identifies pathogenic noncoding somatic mutations from personal prostate cancer genomes.
    Cancer Res. 2020 Sep 9. pii: 0008-5472.CAN-20-1791.
    PubMed     Abstract available


    August 2020
  40. SCHONHOFT JD, Zhao JL, Jendrisak A, Carbone EA, et al
    Morphology-predicted large scale transition number in circulating tumor cells identifies a chromosomal instability biomarker associated with poor outcome in castration-resistant prostate cancer.
    Cancer Res. 2020 Aug 19. pii: 0008-5472.CAN-20-1216.
    PubMed     Abstract available


    June 2020
  41. XU S, Fan L, Jeon HY, Zhang F, et al
    p300-mediated acetylation of histone demethylase JMJD1A prevents its degradation by ubiquitin ligase STUB1 and enhances its activity in prostate cancer.
    Cancer Res. 2020 Jun 10. pii: 0008-5472.CAN-20-0233.
    PubMed     Abstract available


  42. SETTON JS, Powell SN
    Moving beyond PARP Inhibition in ATM-Deficient Prostate Cancer.
    Cancer Res. 2020;80:2085-2086.
    PubMed     Abstract available


    May 2020
  43. LI S, Fong KW, Gritsina G, Zhang A, et al
    Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.
    Cancer Res. 2020;80:2072.
    PubMed    


  44. HARLEMON M, Ajayi O, Kachambwa P, Kim MS, et al
    A custom genotyping array reveals population-level heterogeneity for the genetic risks of prostate cancer and other cancers in Africa.
    Cancer Res. 2020 May 11. pii: 0008-5472.CAN-19-2165.
    PubMed     Abstract available


  45. WAHDAN-ALASWAD RS, Song K, Krebs TL, Shola DTN, et al
    Retraction: Insulin-Like Growth Factor I Suppresses Bone Morphogenetic Protein Signaling in Prostate Cancer Cells by Activating mTOR Signaling.
    Cancer Res. 2020;80:1902.
    PubMed    


    April 2020
  46. WU H, You L, Li Y, Zhao Z, et al
    Loss of a negative feedback loop between IRF8 and AR promotes prostate cancer growth and enzalutamide resistance.
    Cancer Res. 2020 Apr 27. pii: 0008-5472.CAN-19-2549.
    PubMed     Abstract available


  47. MAO N, Gao D, Hu W, Gadal S, et al
    Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2.
    Cancer Res. 2020;80:1428-1437.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: